First Time Loading...

Relay Therapeutics Inc
NASDAQ:RLAY

Watchlist Manager
Relay Therapeutics Inc Logo
Relay Therapeutics Inc
NASDAQ:RLAY
Watchlist
Price: 6.155 USD -3.07%
Updated: Apr 26, 2024

Intrinsic Value

RLAY's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. [ Read More ]

The intrinsic value of one RLAY stock under the Base Case scenario is 0.428 USD. Compared to the current market price of 6.155 USD, Relay Therapeutics Inc is Overvalued by 93%.

Key Points:
RLAY Intrinsic Value
Base Case
0.428 USD
Overvaluation 93%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Relay Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling RLAY stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Relay Therapeutics Inc

Provide an overview of the primary business activities
of Relay Therapeutics Inc.

What unique competitive advantages
does Relay Therapeutics Inc hold over its rivals?

What risks and challenges
does Relay Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Relay Therapeutics Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Relay Therapeutics Inc.

Provide P/S
for Relay Therapeutics Inc.

Provide P/E
for Relay Therapeutics Inc.

Provide P/OCF
for Relay Therapeutics Inc.

Provide P/FCFE
for Relay Therapeutics Inc.

Provide P/B
for Relay Therapeutics Inc.

Provide EV/S
for Relay Therapeutics Inc.

Provide EV/GP
for Relay Therapeutics Inc.

Provide EV/EBITDA
for Relay Therapeutics Inc.

Provide EV/EBIT
for Relay Therapeutics Inc.

Provide EV/OCF
for Relay Therapeutics Inc.

Provide EV/FCFF
for Relay Therapeutics Inc.

Provide EV/IC
for Relay Therapeutics Inc.

Show me price targets
for Relay Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Relay Therapeutics Inc?

How accurate were the past Revenue estimates
for Relay Therapeutics Inc?

What are the Net Income projections
for Relay Therapeutics Inc?

How accurate were the past Net Income estimates
for Relay Therapeutics Inc?

What are the EPS projections
for Relay Therapeutics Inc?

How accurate were the past EPS estimates
for Relay Therapeutics Inc?

What are the EBIT projections
for Relay Therapeutics Inc?

How accurate were the past EBIT estimates
for Relay Therapeutics Inc?

Compare the revenue forecasts
for Relay Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Relay Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Relay Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Relay Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Relay Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Relay Therapeutics Inc with its peers.

Analyze the financial leverage
of Relay Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Relay Therapeutics Inc.

Provide ROE
for Relay Therapeutics Inc.

Provide ROA
for Relay Therapeutics Inc.

Provide ROIC
for Relay Therapeutics Inc.

Provide ROCE
for Relay Therapeutics Inc.

Provide Gross Margin
for Relay Therapeutics Inc.

Provide Operating Margin
for Relay Therapeutics Inc.

Provide Net Margin
for Relay Therapeutics Inc.

Provide FCF Margin
for Relay Therapeutics Inc.

Show all solvency ratios
for Relay Therapeutics Inc.

Provide D/E Ratio
for Relay Therapeutics Inc.

Provide D/A Ratio
for Relay Therapeutics Inc.

Provide Interest Coverage Ratio
for Relay Therapeutics Inc.

Provide Altman Z-Score Ratio
for Relay Therapeutics Inc.

Provide Quick Ratio
for Relay Therapeutics Inc.

Provide Current Ratio
for Relay Therapeutics Inc.

Provide Cash Ratio
for Relay Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Relay Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Relay Therapeutics Inc?

What is the current Free Cash Flow
of Relay Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Relay Therapeutics Inc.

Financials

Balance Sheet Decomposition
Relay Therapeutics Inc

Current Assets 770.1m
Cash & Short-Term Investments 750.1m
Other Current Assets 20m
Non-Current Assets 73.9m
PP&E 68.9m
Intangibles 2.3m
Other Non-Current Assets 2.7m
Current Liabilities 30.3m
Accounts Payable 9.2m
Accrued Liabilities 19.9m
Other Current Liabilities 1.2m
Non-Current Liabilities 61.7m
Other Non-Current Liabilities 61.7m
Efficiency

Earnings Waterfall
Relay Therapeutics Inc

Revenue
25.5m USD
Operating Expenses
-398.5m USD
Operating Income
-373m USD
Other Expenses
31m USD
Net Income
-342m USD

Free Cash Flow Analysis
Relay Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

RLAY Profitability Score
Profitability Due Diligence

Relay Therapeutics Inc's profitability score is 11/100. The higher the profitability score, the more profitable the company is.

11/100
Profitability
Score

Relay Therapeutics Inc's profitability score is 11/100. The higher the profitability score, the more profitable the company is.

RLAY Solvency Score
Solvency Due Diligence

Relay Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Relay Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

RLAY Price Targets Summary
Relay Therapeutics Inc

Wall Street analysts forecast RLAY stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RLAY is 23.516 USD with a low forecast of 10.706 USD and a high forecast of 34.65 USD.

Lowest
Price Target
10.706 USD
74% Upside
Average
Price Target
23.516 USD
282% Upside
Highest
Price Target
34.65 USD
463% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

RLAY Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

RLAY Price
Relay Therapeutics Inc

1M 1M
-19%
6M 6M
-3%
1Y 1Y
-46%
3Y 3Y
-82%
5Y 5Y
-82%
10Y 10Y
-82%
Annual Price Range
6.155
52w Low
5.9
52w High
13.14
Price Metrics
Average Annual Return -19.37%
Standard Deviation of Annual Returns 34.45%
Max Drawdown -90%
Shares Statistics
Market Capitalization 784.5m USD
Shares Outstanding 131 179 000
Percentage of Shares Shorted 10.96%

RLAY Return Decomposition
Main factors of price return

What is price return decomposition?

RLAY News

Other Videos

Company Profile

Relay Therapeutics Inc Logo
Relay Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

784.5m USD

Dividend Yield

0%

Description

Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The company is headquartered in Cambridge, Massachusetts and currently employs 245 full-time employees. The company went IPO on 2020-07-16. The firm is focused on transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The firm is advancing a pipeline of medicines to address targets in precision oncology, including its lead product candidates, RLY-4008, RLY-2608 and RLY-1971. Its RLY-1971 binds and stabilizes Src homology region two (SH2)-containing protein tyrosine phosphatase two (SHP2) in its inactive conformation. Its RLY-4008, is it inhibitor of fibroblast growth factor receptor 2 (FGFR2), enriched for patients with advanced solid tumors having oncogenic FGFR2. The firm uses its Dynamo platform to focus on precision oncology. The company is also advancing several early programs focused on other precision oncology and genetic disease targets.

Contact

MASSACHUSETTS
Cambridge
399 Binney Street, 2Nd Floor
+16173708837.0
https://relaytx.com/

IPO

2020-07-16

Employees

245

Officers

Co-Founder & Independent Chairman
Mr. Alexis A. Borisy A.M.
CEO, President & Director
Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS
Co-Founder & Director
Dr. Mark Murcko Ph.D.
Chief Financial Officer
Mr. Thomas Catinazzo
Chief Legal Officer & Secretary
Mr. Brian R. Adams J.D.
President of Research & Development
Dr. Donald A. Bergstrom M.D., Ph.D.
Show More
Chief Corporate Development Officer
Mr. Peter Rahmer
Vice President of Corporate Development & Strategy
Dr. Deborah Palestrant M.B.A., Ph.D.
Chief Scientific Officer of Late Research
Mr. Jim Watters Ph.D.
Chief Medical Officer & Head of Precision Medicine
Dr. Beni B. Wolf M.D., Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one RLAY stock?

The intrinsic value of one RLAY stock under the Base Case scenario is 0.428 USD.

Is RLAY stock undervalued or overvalued?

Compared to the current market price of 6.155 USD, Relay Therapeutics Inc is Overvalued by 93%.